These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28750313)

  • 1. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors.
    Moarbess G; Guichou JF; Paniagua-Gayraud S; Chouchou A; Marcadet O; Leroy F; Ruédas R; Cuq P; Deleuze-Masquéfa C; Bonnet PA
    Eur J Med Chem; 2016 Jun; 115():268-74. PubMed ID: 27017554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and Selective TLR7 Antagonists among the Imidazo[1,2-
    Bou Karroum N; Moarbess G; Guichou JF; Bonnet PA; Patinote C; Bouharoun-Tayoun H; Chamat S; Cuq P; Diab-Assaf M; Kassab I; Deleuze-Masquefa C
    J Med Chem; 2019 Aug; 62(15):7015-7031. PubMed ID: 31283223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
    Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
    Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors.
    Li B; Cociorva OM; Nomanbhoy T; Weissig H; Li Q; Nakamura K; Liyanage M; Zhang MC; Shih AY; Aban A; Hu Y; Cajica J; Pham L; Kozarich JW; Shreder KR
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5217-22. PubMed ID: 23916259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
    Koch P; Jahns H; Schattel V; Goettert M; Laufer S
    J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines.
    Jain G; Voogdt C; Tobias A; Spindler KD; Möller P; Cronauer MV; Marienfeld RB
    Neoplasia; 2012 Mar; 14(3):178-89. PubMed ID: 22496618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
    Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.
    Sagar S; Singh S; Mallareddy JR; Sonawane YA; Napoleon JV; Rana S; Contreras JI; Rajesh C; Ezell EL; Kizhake S; Garrison JC; Radhakrishnan P; Natarajan A
    Eur J Med Chem; 2021 Oct; 222():113579. PubMed ID: 34098465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
    Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
    Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
    El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
    Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
    Seitz LE; Suling WJ; Reynolds RC
    J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity.
    Parra S; Laurent F; Subra G; Deleuze-Masquefa C; Benezech V; Fabreguettes J; Vidal J; Pocock T; Elliott K; Small R; Escale R; Michel A; Chapat J; Bonnet P
    Eur J Med Chem; 2001 Mar; 36(3):255-64. PubMed ID: 11337104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.